Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Instagram Outage Disrupts Thousands of U.S. Users 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
SEATTLE and PHILADELPHIA, March 21, 2018 -- Nohla Therapeutics, a leading developer of universal donor cell therapies for patients with hematologic malignances and other critical diseases, and WuXi AppTec Advanced Therapies, a streamlined Contract Development and Manufacturing Organization (CDMO), have entered into a commercial agreement for production of Nohla’s NLA101, a universal donor, ex vivo expanded hematopoietic stem and progenitor cell product.
“We are excited to partner with WuXi AppTec Advanced Therapies to gain their expertise and cGMP manufacturing capabilities to support the ongoing development and anticipated global commercial demand for our lead cell therapy program, NLA101,” said Katie Fanning, President and Chief Executive Officer of Nohla.
“We are very pleased to enter into this manufacturing partnership with Nohla,” said Felix Hsu, Senior Vice President and Head of WuXi AppTec Advanced Therapies. “With our integrated manufacturing services, we believe we can bring speed and reliability to the manufacturing needs of Nohla and support the rapid advance of their clinical timelines. We are committed to helping our partners deliver these innovative therapies to patients and the market sooner.”
WuXi AppTec Advanced Therapies will manufacture Nohla’s universal cell therapies in their 55,000 square foot commercial manufacturing facility for cell therapies, one of three facilities in the Philadelphia Navy Yard supporting the development, manufacturing, and quality control testing of cell and gene therapies.
About Nohla Therapeutics
Nohla Therapeutics is a clinical stage cell therapy company that’s redefining clinical outcomes for patients with critical diseases by providing a short-term hematopoietic bridge to immune repair and healthy blood production with long-term immunologic benefits. Nohla’s proven platform generates universal, off-the shelf therapies that enable improved clinical outcomes across a number of disease indications, with an initial focus on high-risk hematological malignancies. Nohla's lead candidate, NLA101, is an expanded progenitor cell therapy that provides the functional support of bone marrow in response to each patient’s unique blood-production needs, without any requirement for HLA matching. The product has demonstrated the potential for robust efficacy in multiple clinical trials, while overcoming the broad safety and logistical risks of patient-customized cell therapies. More information is available at www.nohlatherapeutics.com.
About WuXi AppTec
WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost effective and efficient solutions. The Advanced Therapies business unit of WuXi AppTec is a Contract Development and Manufacturing Organization (CDMO) that reduces the complexities of the high-touch, multi-vendor biopharmaceutical production model by providing platforms that enable cell and gene therapies to be developed, manufactured, and released faster and with greater predictability. Since 2004, WuXi AppTec has supported Advanced Therapy manufacturing programs from their Philadelphia, PA campus which today includes over 220,000 square feet of GMP compliant manufacturing space. For more information visit http://www.wuxiapptec.com.
Media Contacts: Nohla Therapeutics Jim DeNike Senior Director, Corporate Development & Investor Relations 206.519.5294 [email protected] WuXi AppTec Advanced Therapies Jason Noga Marketing Manager 215.593.5464 [email protected]
